<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260714070195N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-19</date_registration>
      <primary_sponsor>Ilam University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the Effect of Propofol Anesthesia (TIVA) versus Isoflurane on the Incidence of Postoperative Delirium Based on Sex Differences in Adults Undergoing Abdominal Surgery</public_title>
      <acronym>TIGER-ED</acronym>
      <scientific_title>Comparison of the effects of total intravenous anesthesia ( TIVA with propofol) versus inhalational anesthesia (Isufluran) on the incidence of emergence delirium based on gender differences in adults undergoing abdominal surjeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>200</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/92196</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: None, Randomization description: Randomization method: Balanced Block Randomization

Randomization unit: Individual (each patient is randomized separately)

Stratification factors: No stratification is used in this study.

Randomization tool: Random number table

Sequence generation: Blocks with different permutations including (ABBA, ABAB, AABB, BBAA, BABA, BAAB) are created, where A represents the TIVA with propofol group and B represents the isoflurane group. Then, based on a random number table, the allocation sequence is determined to maintain group balance and blinding.

Allocation concealment: The study drugs (propofol solution and isoflurane liquid) are prepared in identical containers without any label indicating the group and are provided to the anesthesiologist. Only the principal investigator has access to the randomization codes, Blinding description: This study uses a double-blind design. Blinding is implemented as follows:

1. Participants (Patients): Patients receive complete information about the study one day before surgery but are unaware of the type of anesthesia method assigned to them.
2. Anesthesiologist (Intervention provider): Although the anesthesiologist is aware of the administered drug, all drugs are prepared in identical containers without any group-identifying labels to minimize selection bias.
3. Surgeon: The surgeon is blinded to the anesthesia method.
4. Recovery room nurses (Clinical caregivers): Nurses responsible for patient care and assessment in the post-anesthesia care unit (PACU) are blinded to the group allocation.
5. Outcome assessors: Trained nurses who administer the CAM-ICU and CAM questionnaires for delirium assessment are completely blinded to the patients' group allocation.
6. Principal investigator: The principal investigator has access to the randomization codes but is not involved in outcome assessment. However, the codes will be used for final data analysis.
7. Data analyst: The individual performing statistical analysis is blinded to group allocation to prevent bias in data interpretation.
8. Allocation concealment: Study drugs (propofol solution and isoflurane liquid) are prepared in identical containers without any group-identifying labels and are provided to the anesthesiologist. Only the principal investigator has access to the randomization codes and is not involved in drug administration.</study_design>
      <phase>3</phase>
      <hc_freetext>Delirium.</hc_freetext>
      <i_freetext>Intervention 1: In this group, Total Intravenous Anesthesia (TIVA) is performed using Propofol. The induction dose of Propofol is administered intravenously at [exact number] mg/kg. For maintenance of anesthesia, a continuous infusion of Propofol is set at [exact number] mcg/kg/min. Propofol manufactured by [Company Name], with a concentration of 1% (10 mg/ml), will be used. Intervention 2: In this group, inhalation anesthesia is performed using Isoflurane. Induction of anesthesia is performed via a face mask or after tracheal intubation. Isoflurane is administered to the patient through the anesthesia machine at a concentration of [exact number] MAC. For maintenance of anesthesia, the Isoflurane concentration is set at [100]%. Isoflurane manufactured by [Abbott India limited], with a concentration of [100%], will be used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Individual Participant Data (IPD) from a randomized clinical trial comparing TIVA with propofol versus isoflurane on emergence delirium in abdominal surgery

When:
Data will be available after publication of the main results (expected 12 months after study completion) and will remain accessible for 5 years.

To whom:
Qualified researchers from academic institutions with a valid research proposal and ethics approval, upon reasonable request to the corresponding author (Atieh Zolfaghari, zola69440@gmail.com)

Conditions:
The de-identified IPD and supporting documents (protocol, SAP, data dictionary) may be used exclusively for: (1) secondary analyses related to postoperative cognitive outcomes, delirium, or anesthetic techniques; (2) systematic reviews and meta-analyses; (3) methodological validation or replication studies. Users must not use the data for commercial purposes, must maintain confidentiality, and must cite the original study in any resulting publications. Any secondary analysis must be approved by the corresponding author and the ethics committee of the user's institution.

Where to obtain:
Requests for data and supporting documents should be directed to the corresponding author: Atieh Zolfaghari, Department of Anesthesiology, Ilam University of Medical Sciences, Ilam, Iran. Email: zola69440@gmail.com. Postal address: Ilam University of Medical Sciences, Ilam, Iran. Telephone: +98-9964871066.

How to obtain:
The request process includes the following steps: (1) The applicant submits a formal request via email to the corresponding author, including a brief research proposal, intended analysis plan, and ethics approval from their institution. (2) The request is reviewed by the research team for scientific validity and ethical compliance. (3) If approved, the applicant signs a data-sharing agreement ensuring confidentiality, non-commercial use, and proper citation. (4) The de-identified data and relevant documents are shared via a secure online repository (e.g., Zenodo or Figshare) with a password-protected link. The entire process is expected to take approximately 2-4 weeks.

Comments:
This study is registered in the Iranian Registry of Clinical Trials (IRCT). The full protocol and SAP are available as supplementary materials in the main publication. Any publications using these data should cite the primary study and acknowledge the funding source (Ilam University of Medical Sciences).</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Atiyeh zolfaghari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Salman farsi st</address>
        <city>Eyvan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6941914485</zip>
        <telephone>+98 84 3323 3855</telephone>
        <email>zola69440@gmail.com</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Atiyeh zolfaghari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Salman farsi st</address>
        <city>Eyvan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6941914485</zip>
        <telephone>+98 84 3323 3855</telephone>
        <email>zola69440@gmail.com</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 18 to 65 years
Undergoing abdominal surgery with general Anesthesia
ASA physical status class I or II</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of serious psychiatric illness
Pre-existing cognitive disorders
Hepatic or renal failure
Substance abuse
Hypersensitivity to study drugs (propofol, isoflurane, etc.)
Pregnancy or lactation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In this group, Total Intravenous Anesthesia (TIVA) is performed using Propofol. The induction dose of Propofol is administered intravenously at [exact number] mg/kg. For maintenance of anesthesia, a continuous infusion of Propofol is set at [exact number] mcg/kg/min. Propofol manufactured by [Company Name], with a concentration of 1% (10 mg/ml), will be used.</i_keyword>
      <i_keyword>In this group, inhalation anesthesia is performed using Isoflurane. Induction of anesthesia is performed via a face mask or after tracheal intubation. Isoflurane is administered to the patient through the anesthesia machine at a concentration of [exact number] MAC. For maintenance of anesthesia, the Isoflurane concentration is set at [100]%. Isoflurane manufactured by [Abbott India limited], with a concentration of [100%], will be used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Incidence of postoperative delirium (POD) diagnosed using the standardized NUDESC (Nursing Delirium Screening Scale) at multiple time points including the PACU period, as well as 6 and 12 hours after surgery. This tool consists of 5 key items assessing the presence or absence of delirium symptoms. The total score ranges from 0 to 5, and a score of 2 or higher (NUDESC ≥ 2) is considered a positive diagnosis of delirium. Timepoint: Delirium assessment using the NUDESC tool is performed at five time points:1. Upon admission to the PACU (immediately after transfer from the operating room)2. 30 minutes after PACU admission3. At the time of PACU discharge (when discharge criteria are met)4. 6 hours after surgery (in the ward)5. 12 hours after surgery (in the ward). Method of measurement: Assessment is performed by trained and blinded nurses using the standardized NUDESC tool. The nurse, through direct patient observation, medical record review, and interview with the patient's companion (if necessary), evaluates the presence or absence of each of the following 5 signs:1. Disorientation2. Inappropriate behavior3. Inappropriate communication4. Hallucination/Delusion5. Psychomotor retardation/agitationEach sign scores 1 point, and the total score ranges from 0 to 5. A score of ≥ 2 is considered a positive diagnosis of delirium.Simultaneously with delirium assessment at these time points, hemodynamic parameters including Mean Arterial Pressure (MAP), Heart Rate (HR), and Arterial Oxygen Saturation (SpO₂) are also recorded and evaluated to assess the relationship between hemodynamic changes and the occurrence of delirium.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ilam University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-07-14</approval_date>
        <contact_name>Ilam University of Medical Sciences Research Ethics Committee</contact_name>
        <contact_address>Salman farsi st Eyvan Ilam Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
